These are the stocks posting the largest moves before the bell.Market Insiderread more
The Fed is expected to cut rates Wednesday, but it is unlikely to tell markets what they want to hear on future rate cuts.Market Insiderread more
Corporate executives and money managers have grown increasingly pessimistic about the economy as growth around the world slows.Trader Talk with Bob Pisaniread more
Facebook unveils the Portal TV, a streaming device that comes with a camera and microphones for making video calls via television.Technologyread more
Four Wall Street firms downgraded FedEx after the company's poor earnings report.Marketsread more
FedEx says trade around the world is starting to feel the squeeze of increased tariffs.Marketsread more
U.S. stock futures point to a modestly lower Wednesday morning open on Wall Street ahead of what the markets in the afternoon expect to be the Fed's second interest rate cut...Marketsread more
Mortgage applications to purchase a home increased 6% for the week and were a strong 15% higher annually.Real Estateread more
The House subcommittee that oversees consumer product investigations launched its a probe of Juul in June, holding two days of hearings in July. In a letter to Juul sent...Health and Scienceread more
Pelosi said Trump should not have tried to address China's trade practices in a way that opened Americans up to financial pain.Politicsread more
Corporate buyback trades are ripe for being picked off by high speed firms, effectively siphoning millions of dollars from the companies.Marketsread more
Americans are increasingly in favor of more federal regulation to rein in drug prices, including letting the government negotiate directly with drugmakers for the Medicare program, according to a new survey from the Kaiser Family Foundation.
Yet the poll also found that respondents are leery of potential consequences.
About 90 percent respondents to the health tracking survey favor two measures proposed by the Trump administration: requiring drug companies to include list prices in their advertising and making it easier for generic drugs to come to market. Kaiser surveyed 1,440 adults from Feb. 14 through Feb. 24.
A large majority also want Washington to go further when it comes to drugs for Medicare patients. Eighty-six percent support allowing the government to negotiate drug prices for Medicare, with 90 percent of Democrats and 80 percent of Republicans favoring the measure.
There's much less consensus on direct negotiations in Washington. While House Democrats have introduced a bill requiring the Centers for Medicare and Medicaid Services to negotiate with drugmakers directly for Medicare Part D drug plans, opposition is strong among Republicans.
"I don't want the government negotiating," Sen. Chuck Grassley, R-Iowa, told CNBC, adding that he opposes the Trump administration's proposal to bring Medicare drug prices closer to those paid by other industrial countries by using an international price benchmark.
"I want (prices) negotiated in the free market — I want a willing buyer and a willing seller to make that decision," said Grassley, chairman of the Senate Finance Committee.
During the committee's drug price hearing last week, AbbVie CEO Richard Gonzalez admitted that American consumers pay higher prices than people in other countries for his company's flagship arthritis drug Humira, but he maintained that dramatically cutting prices in the United States would effectively limit the company's ability to fund innovation and research into new treatments.
"Our system is built around a variety of pricing, around the world, but that overall system supports our R&D model," Gonzalez said.
The panel's top Democrat, Sen. Ron Wyden of Oregon, had a withering rebuke for that argument.
"If lower prices would diminish R&D, why don't costly dividends? Why don't stock buybacks? Is the stock price more important than inventing the next miracle cure?" Widen asked.
But the potential for less innovation is an issue that resonates in the recent Kaiser tracking poll.
Support for price negotiation dropped from 86 percent to just 31 percent if government price negotiations could hurt research and development. Support dropped just as sharply when presented with the argument that it could lead to Medicare not covering some prescription drugs.
A decade ago, a similar question on a Kaiser tracking poll found that nearly 48 percent supported increased price regulations even if it might lead to less R&D.
In the current era when new immunotherapy drugs have led to greater success in treating some cancers, and there is a growing need for innovative treatments for diseases like Alzheimer's, Americans may be less willing to make that trade off. They just want Washington to find a way to make drugs now more affordable.